The acceptable duration between occupational exposure to hepatitis B virus and hepatitis B immunoglobulin injection: Results from a Korean nationwide, multicenter study - 23/01/16

Abstract |
Background |
Postexposure prophylaxis for occupational exposure to hepatitis B virus (HBV) plays an important role in the prevention of HBV infections in health care workers (HCWs). We examined data concerning the acceptable duration between occupational exposure and administration of a hepatitis B immunoglobulin (HBIG) injection in an occupational clinical setting.
Methods |
A retrospective analysis was conducted with data from 143 cases of HCWs exposed to HBV in 15 secondary and tertiary teaching hospitals between January 2005 and June 2013. Data were taken from the infection control records of each hospital.
Results |
Active vaccination after HBV exposure was started in 119 cases (83.2%) and postvaccination testing for hepatitis B antibody showed positive seroconversion in 93% of cases. In 98 cases (68.5%), HBIG was administered within 24 hours after HBV exposure; however, 45 HCWs (31.5%) received an HBIG injection more than 24 hours postexposure and 2 among the 45 received an injection after 7 days. Although 31.5% received an HBIG injection more than 24 hours postexposure, no cases of seroconversion to hepatitis b antibody positivity occurred.
Conclusions |
For susceptible HCWs, HBIG administered between 24 hours and 7 days postexposure may be as effective as administration within 24 hours in preventing occupational HBV infection.
Le texte complet de cet article est disponible en PDF.Highlights |
• | The effectiveness of late occupational PEP for HBV after 24 hours was not known. |
• | A retrospective analysis was done with data from 143 cases of HCWs in Korea. |
• | No case of seroconversion of HBsAg was found even in late HBV PEP group. |
• | HBIG administered between 24 hours and 7 days of post-exposure may not be harmful. |
Key Words : Postexposure prophylaxis, Occupational exposure, Hepatitis B virus, Health care workers, Treatment outcomes
Plan
| H-HC, CM, WS C, H-JY, JK, SYR, HAK, YMJ, KTK, HIK, YKY, SIJ, K-HP, HHK, MSL, JH, and S-WK are members of the Antibiotics Stewardship Study Group of the Korean Society for Chemotherapy. |
|
| This work was supported by the Korean Society for Chemotherapy. |
|
| Conflicts of interest: None to report. |
Vol 44 - N° 2
P. 189-193 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
